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A B S T R A C T
Rotavirus infection has emerged as an important cause of complications in organ transplantation recipients and
might play a role in the pathogenesis of inﬂammatory bowel disease (IBD). 6-Thioguanine (6-TG) has been
widely used as an immunosuppressive drug for organ recipients and treatment of IBD in the clinic. This study
aims to investigate the eﬀects and mode-of-action of 6-TG on rotavirus replication. Human intestinal Caco2 cell
line, 3D model of human primary intestinal organoids, laboratory rotavirus strain (SA11) and patient-derived
rotavirus isolates were used. We have demonstrated that 6-TG signiﬁcantly inhibits rotavirus replication in these
intestinal epithelium models. Importantly, gene knockdown or knockout of Rac1, the cellular target of 6-TG,
signiﬁcantly inhibited rotavirus replication, indicating the supportive role of Rac1 for rotavirus infection. We
have further demonstrated that 6-TG can eﬀectively inhibit the active form of Rac1 (GTP-Rac1), which essen-
tially mediates the anti-rotavirus eﬀect of 6-TG. Consistently, ectopic over-expression of GTP-Rac1 facilitates but
an inactive Rac1 (N17) or a speciﬁc Rac1 inhibitor (NSC23766) inhibits rotavirus replication. In conclusion, we
have identiﬁed 6-TG as an eﬀective inhibitor of rotavirus replication via the inhibition of Rac1 activation. Thus,
for transplantation patients or IBD patients infected with rotavirus or at risk of rotavirus infection, the choice of
6-TG as a treatment appears rational.
1. Introduction
Rotavirus, a double stranded RNA (dsRNA) virus in the Reoviridae
family, is a major cause of gastroenteritis, particularly in children
younger than 5 years of age. As a major global health problem, this
virus causes 114 million diarrhea episodes, 2.4 million hospitalizations,
and an estimated 215,000 deaths worldwide annually (Grimwood and
Buttery, 2007; Tate et al., 2016). Although rotavirus infection mainly
occurs in developing countries, it also results in over 200 deaths and
more than 87,000 hospital admissions in infants in European Union
(Vesikari et al., 2007). Besides young children, organ transplantation
patients are also susceptible to rotavirus infection irrespective of their
age, causing long-term diarrhea and even death due to graft failure (Yin
et al., 2015b). Although two global licensed rotavirus vaccines have
been launched, no speciﬁc antiviral treatment is available.
A thio analogue of the naturally occurring purine base guanine, 6-
thioguanine (6-TG), has been used in the clinic since the early 1950s
(Munshi et al., 2014). 6-TG was initially developed to treat cancer;
whereas currently it is widely used as an immunosuppressive agent in
organ transplantation. It is also used as treatment for acute lympho-
blastic leukemia in children and for autoimmune diseases (Bourgine
et al., 2011). In particular, 6-TG is often used to treat inﬂammatory
bowel disease (IBD) (de Boer et al., 2006). IBD including Crohn's dis-
ease (CD), ulcerative colitis (UC) and indeterminate colitis (IC) re-
present a heavy burden in Western countries (Kolho et al., 2012). Al-
though the causes of exacerbations of IBD remain poorly characterized,
gastrointestinal infections including rotavirus might induce ﬂares in
IBD (Masclee et al., 2013). Thus, preventing or treating rotavirus in-
fection in these patients is of importance.
Upon ingestion, 6-TG is ﬁrst metabolized into 6-thioguanosine
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Fig. 1. 6-TG eﬀectively inhibits rotavirus replication. (A) Treatment with 6-TG (48 h) signiﬁcantly inhibited viral genomic RNA in SA11 rotavirus infected Caco2
cells (MOI = 0.7) in a dose-dependent manner (n = 6–17, means ± SEM, *P < 0.05, ***P < 0.001, Mann-Whitney test, A.U. denotes artiﬁcial unit). (B) Eﬀects of
6-TG on the production of infectious viral particles determined by TCID50 method. Each bar represents the TCID50/mL (mean ± SEM) (n = 3, P < 0.05, Mann-
Whitney test). (C) Treatment with 6-TG (48 h) signiﬁcantly inhibited viral VP4 protein in SA11 rotavirus infected Caco2 cells in a dose-dependent manner (the
densitometric analysis of immunoreactive bans in western bots was quantiﬁed by ImageJ software, and the ratio of VP4/β-actin was expressed in arbitrary units). (D)
Treatment with 6-TG (6–48 h) signiﬁcantly inhibited viral genomic RNA in SA11 rotavirus infected Caco2 cells (MOI = 0.7) in a time-dependent manner (n = 4–8,
means ± SEM, *P < 0.05, **P < 0.01, Mann-Whitney test, p.i.h denotes hour of post infection). (E) The morphology of human primary small intestinal organoids
with clear villus domain and crypt domain. (F) Treatment with 6-TG (48 h) signiﬁcantly inhibited genomic RNA in SA11 rotavirus (MOI = 7) infected human
intestinal organoids (n = 6, means ± SEM, *P < 0.05, Mann-Whitney test). (G) Treatment with 6-TG (48 h) signiﬁcantly inhibited viral production in SA11
rotavirus infected human intestinal organoids (n = 6, means ± SEM, **P < 0.01, Mann-Whitney test). (H) Treatment with 100 ng/mL of 6-TG (48 h) inhibited viral
RNA of patient-derived rotavirus isolates in Caco2 cells. (I) Treatment with 100 ng/mL of 6-TG (48 h) inhibited viral RNA of patient-derived rotavirus isolates in
human intestinal organoids.
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monophosphate (6-TGMP), and subsequently into 6-thioguanosine di-
phosphate (6-TGDP), and ﬁnally into 6-thioguanosine triphosphate (6-
TGTP) (Chouchana et al., 2012). Among these metabolites, 6-TGDP and
6-TGTP are able to compete with endogenous guanosine phosphates for
Rac1 binding and to form 6-TGNP•Rac1 complexes. These complexes
are in turn incapable to support the formation of the active
Fig. 2. 6-TG has a high barrier to drug resistance development. Rotavirus was serially passaged in MA104 or Caco2 cells exposed to no 6-TG (as control) and
increasing concentrations of 6-TG until 20 passages (infected cultures were exposed to 1000 ng/mL of 6-TG in passage 1–10; whereas the drug concentration was
increased to 2000 ng/mL at the subsequent later passages). The eﬀect of 6-TG (100 ng/mL) on passage 5, 10, 15 and 20 (the drug treated and untreated) of rotavirus
was quantiﬁed using qRT-PCR. 6-TG retained its anti-rotavirus activity even with continuous exposure to 6-TG for 20 passages in MA104 cells (A) and Caco2 cells (B).
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conﬁguration of Rac1, a process that Rac1 interacts with GTP. Thus, 6-
TG indirectly provokes inhibition of Rac1-dependent signaling (Shin
et al., 2016), which has substantial consequences for cellular phy-
siology. As a member of the Ras superfamily of Rho GTPases, GTP-
bound Rac1 mediates a myriad of cellular processes including actin
reorganization and gene transcription. Intriguingly, IBD is character-
ized by hyperactivation of Rac1 in the phagocyte compartment. This is
associated with reduced eﬀector function of Rac1, which is sensitive to
6-TG treatment (Parikh et al., 2014). The inhibition of Rac1 resulting
from 6-TG treatment restores innate immune functionality of phago-
cytes in IBD patients, contributing to disease remission (Parikh et al.,
2014). Thus, Rac1 hyperactivation appears an important im-
munosuppressive eﬀector in human pathophysiology, at least in the
phagocyte compartment.
Given the clinical relevance and the potential in revealing me-
chanistic insight, we have investigated the eﬀects and mechanism-of-
action of 6-TG on rotavirus replication. To this end, we have demon-
strated that 6-TG eﬀectively combats rotavirus replication through in-
hibition of Rac1 activation.
2. Materials and methods
2.1. Viruses and reagents
Simian rotavirus SA11 strain and patient-derived rotavirus isolates
(G1P[8]) were prepared as previously described (Yin et al., 2015a,
2016).
Stocks (0.1 mg/mL) of 6-TG (Sigma-Aldrich) were dissolved in alkali
solution (1M NaOH, 50mg/mL), and NSC23766 (Merck Millipore) was
dissolved in H2O (2mM). All chemicals were stored in 25 μL aliquots
and frozen at −80 °C.
2.2. Conventional enterocyte culture and human primary intestinal
organoid culture
Human colon cancer cell line Caco2 and human embryonic kidney
cell line 293 T (HEK 293 T) cells were grown in Dulbecco's modiﬁed
Eagle medium (DMEM) (Invitrogen-Gibco, Breda, The Netherlands)
supplemented with 20% (vol/vol) heat-inactivated fetal calve serum
(FCS) (Hyclone, Lonan, Utah) and Penicillin (100 IU/mL)/streptomycin
(100mg/mL) (Invitrogen-Gibco) at 37 °C in a humidiﬁed 5% CO2 in-
cubator. Rac1 knockout mouse embryonic ﬁbroblast (MEF) cells were
cultured in DMEM supplemented with 10% FCS, Penicillin (100 IU/
mL)/streptomycin (100mg/mL), L-Glutamine (Gibco® by Life
Technologies), non-essential amino acids (Gibco® by Life Technologies)
and sodium-pyruvate (Gibco® by Life Technologies). Caco2 cells with
stable knockdown of Rac1 were generated by transduction of lentiviral
shRNA (produced in HEK293T cells) targeting Rac1 and selected with
puromycin (6 μg/mL) as described previously (Yin et al., 2016). The
shRNA targeting sequences used in this study were listed in Table S1.
3D culture of human intestinal organoids was performed as pre-
viously described (Yin et al., 2015a).
2.3. Rotavirus inoculation and drug treatment
Inoculation and treatment of Caco2 cells and human intestinal or-
ganoids with SA11 and patient-derived rotavirus were performed as
previously described (Yin et al., 2016).
Fig. 3. Rac1, the drug target of 6-TG, sustains rotavirus replication. (A) Western blot assay detected Rac1 in transduced Caco2 cells transduced lentiviral RNAi
vectors against Rac1 (The ratio of Rac1/β-actin was expressed in arbitrary units). (B) Three (No. 9687, 9689 and 9690) out of ﬁve lentiviral shRNA vectors inhibited
rotavirus genomic RNA (n = 6–10, means ± SEM, *P < 0.05, ***P < 0.001, Mann-Whitney test). (C) Western blot assay conﬁrmed knockout of Rac1 in Rac1
knockout (−/−) MEF cells. (D) SA11 rotavirus replication was signiﬁcantly attenuated in Rac1 knockout (−/−) MEF cells (n = 4, means ± SEM, *P < 0.05,
Mann-Whitney test).
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2.4. Viability assay of cells or organoids
The viability of cells or organoids was determined by 3-(4, 5-
Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay.
Brieﬂy, Caco2 cells (1× 104 cells/well) or organoids were seeded into a
96-well culture plate and incubated with various concentrations of 6-
TG or NSC23766 for 48 h, followed by adding 500 μg/mL of MTT so-
lution to each well and incubation at 37 °C for 3 h. Subsequently, the
medium was removed, and replaced with 100 μL DMSO and incubated
at 37 °C for 50min. Then, the absorbance was measured at 490 nm in an
enzyme-linked immunosorbent assay reader (BIO-RAD). The eﬀects of
6-TG, NSC294002, IFNα and ribavirin on host cell viability were
Fig. 4. The activation form of Rac1 is required for supporting rotavirus replication. (A) Schematic depicting the pull-down assay. (B) NSC23766 inhibited GTP-Rac1
detected by pulldown assay (The ratio of GTP-Rac1/Rac was expressed in arbitrary units). (C) Treatment with NSC23766 (48 h) signiﬁcantly inhibited viral genomic
RNA in SA11 rotavirus infected Caco2 cells in a dose-dependent manner (n = 8–10, means ± SEM, *P < 0.05, ***P < 0.001, Mann-Whitney test). (D) Treatment
with NSC23766 (48 h) signiﬁcantly inhibited viral VP4 protein in SA11 rotavirus infected Caco2 cells in a dose-dependent manner (The ratio of VP4/β-actin was
expressed in arbitrary units). (E) Treatment with NSC23766 (48 h) signiﬁcantly inhibited viral RNA in SA11 rotavirus infected human intestinal organoids (n = 6,
means ± SEM, *P < 0.05, Mann-Whitney test). (F) Flow cytometric analysis of green ﬂuorescence indicated the percentages of transduced cells with Rac1V12 and
Rac1N17 plasmids. Median ﬂuorescence identity (MFIs) of control, N17 and V12 are 3.43, 35.5 and 84.3, respectively. (G) Pull-down and western blot assays showed
higher level of GTP-Rac1 with transduction of Rac1V12 but lower level of GTP-Rac1 with Rac1N17 plasmids (The ratio of GTP-Rac1/Rac was expressed in arbitrary
units). (H) Detection of phospho-PAK2 indicated successful transduction of Rac1V12 and Rac1N17 plasmids. (I) Rac1V12 transduction facilitates but Rac1N17
inhibits rotavirus replication (n = 10, means ± SEM, *P < 0.05, Mann-Whitney test).
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determined by MTT assay (Fig. S1).
2.5. Transfection of plasmids
A constitutively active Rac1V12 and dominant inactive Rac1N17
plasmids were prepared as previously described (Apolloni et al., 2013).
HEK 293 cells were seeded into 6-well plates for Rac activation assay or
48-well plates for infection assay with ∼70% conﬂuence. The cells
were washed with PBS, followed by adding 500 μL of Opti-MEM® re-
duced serum medium with 2 μg Rac1V12 or Rac1N17 plasmids and
10 μg polyethylenimine (PEI) per well of a 6-well plate, or 100 μL of
Opti-MEM® reduced serum medium (Thermo Fisher Scientiﬁc) with
0.25 μg Rac1V12 or Rac1N17 plasmids and 1.25 μg polyethylenimine
(PEI) (Sigma-Aldrich) per well of a 48-well plate. After 4–5 h of in-
cubation, 2mL or 0.5mL of DMEM containing 10% FCS was added to
each well of 6-well plate or 48-well plate, respectively. Transfected cells
were infected with rotavirus for 24 h.
2.6. Quantitative real-time PCR (qRT-PCR)
Total cellular RNA was isolated using a NucleoSpin® RNA kit
(MACHEREY-NAGEL, Düren, Germany) following the manufacturer's
protocol, and quantiﬁed with a Nanodrop ND-1000 (Wilmington, DE,
USA). cDNA was synthesized using the reverse transcription system
from TAKARA according to manufacturer's instructions (TAKARA BIO
INC). The resulting cDNA was diluted 1:10, and 2 μL of the diluted
cDNA was used for qRT-PCR with primers listed in Table S1. All qRT-
PCR experiments were performed by SYBR-Green-based (Applied Bio-
systems SYBR Green PCR Master Mix; Thermo Fisher Scientiﬁc Life
Science) real-time PCR with the StepOnePlus System (Thermo Fisher
Scientiﬁc Life Sciences). The expression of target mRNA was normal-
ized to the glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
mRNA. Gene expression analysis was performed by the ΔΔCT method
(Yin et al., 2015a, 2016).
2.7. Rac activation assay
The levels of Rac1-bound GTP were detected using Rac interactive
binding (CRIB) domain of PAK (aa56-272) as described previously
(Fuhler et al., 2008). In brief, GST-PAKcrib protein was pre-coupled to
glutathione-Sepharose beads (Sigma-Aldrich) for 45min at 4 °C. Caco2
cells treated with various concentrations of 6-TG or NSC23766 (48 h,
seeded in 6-well-plate) were lysed for 10min in lysis buﬀer (50mM
Tris, pH 7.4, 10% glycerol, 200mM NaCl, 1% NP-40, 2mM MgCl2,
2 mM sodium orthovanadate, and protease inhibitors). Cell lysates were
incubated with pre-coupled beads for 45min. Then, agarose beads were
washed 3 times with 1x lysis buﬀer, followed by boiling in Laemmli
buﬀer, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE, 15%) analysis.
2.8. Western blotting
Cell lysates were subjected to SDS-PAGE, and proteins were trans-
ferred to PVDF membrane (Immobilon-FL). Rac1 monoclonal antibody
(1:1000, rabbit; cell signaling) and SA11 rotavirus VP4 [1:1000, HS-2, a
mouse monoclonal antibody (provided by Professor Harry Greenberg,
Stanford University School of Medicine, USA)] were detected by
Western blotting analysis. Detection of β-actin was served as loading
control (1:1000, mouse monoclonal; Santa Cruz) as previously de-
scribed (Versteeg et al., 2002).
2.9. Serial passaging of rotavirus with 6-TG treatment
To investigate whether rotavirus can develop resistance to 6-TG
treatment, viruses were passaged in both MA104 and Caco2 cells in the
absence of drug (vehicle control) or in the presence of gradually in-
creasing concentrations of the drug (1000 ng/mL of 6-TG for passage
1–10 and 2000 ng/mL of 6-TG for passage 11–20). In brief, MA104 or
Caco2 cells in 24-well plate were inoculated with 200 μL virus
(MOI=0.7) at 37 °C for 1 h, followed by adding 6-TG or without drug
(as control). After 48 h, both cells and supernatant were harvested,
subsequently frozen, thawed once, and centrifuged. The supernatant
containing passaged viruses was stored at−80 °C until used for the next
passage. Viruses were serially passaged by using 1 aliquot of viral stock
from the preceding passage to infect fresh MA104 or Caco2 cells. The
eﬀect of each passage of virus (same titer) was quantiﬁed by qRT-PCR.
Fig. 5. 6-TG inhibits rotavirus via suppression of
Rac1 activation. (A) Anti-rotavirus eﬀect of 6-TG
(100 ng/mL) was attenuated in Rac1 knockdown
Caco2 cells (The ratio of VP4/β-actin was expressed
in arbitrary units). (B) 6-TG inhibited GTP-Rac1 de-
tected by pull-down assay. (C) Anti-rotavirus eﬀect of
NSC23766 (25 μg ng/mL) was attenuated in Rac1
knockdown Caco2 cells. (D) The anti-rotavirus eﬀect
of 6-TG (100 ng/mL) was attenuated in Rac1
knockout (−/−) MEF cells (n = 6–8,
means ± SEM, *P < 0.05, **P < 0.01, Mann-
Whitney test).
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2.10. IC50 and CC50 calculation
IC50 and CC50 calculation were described previously (Yin et al.,
2016).
2.11. Statistics
Data are presented as means, and statistical comparison between
diﬀerent groups was performed by Mann-Whitney test (two-tailed)
using GraphPad Prism 5. Error bars represent the SEM, and P
value<0.05 was considered statistically signiﬁcant.
3. Results
3.1. 6-TG remarkably inhibits rotavirus replication
To assess the eﬀects of 6-TG on rotavirus replication, we treated
SA11 rotavirus-infected Caco2 cells with various concentrations
(0.001–10000 ng/mL) of 6-TG for 48 h. This resulted in dose-dependent
inhibition of rotavirus RNA replication (Fig. 1A, n = 3–17, *P < 0.05,
***P < 0.001). The IC50 value of 6-TG against SA11 rotavirus was
3.0×10−13 M, which is substantially below the concentrations
reached in patients undergoing 6-TG or azathioprine therapy. CC50 of 6-
TG to Caco2 cells was 9.8×10−6 M and selectivity index (SI, CC50/
IC50) was 3.3×107 (Table S2). This was further conﬁrmed at the in-
fectious virus production levels and protein levels of the rotavirus VP4
protein (Fig. 1B and C). To further verify the eﬀect of 6-TG on rotavirus
replication, SA11 rotavirus-infected Caco2 cells were treated with 6-TG
at diﬀerent time points (6, 12, 24 and 48 h), demonstrating that 6-TG
signiﬁcantly inhibited rotavirus RNA replication in time-dependent
Manner (Fig. 1D, n = 4–8, *P < 0.05, **P < 0.01). These results
were substantiated by experiments in human primary intestinal orga-
noids, a model system that recapitulates many aspects of the intestinal
epithelium, including the presence of a villus domain and a crypt do-
main (Fig. 1E) (Sato and Clevers, 2013). 6-TG signiﬁcantly inhibited
SA11 rotavirus replication and virus production in these organoids
(Fig. 1F and G, n = 6, *P < 0.05, **P < 0.01). Our results were
essentially repeated using ﬁve patient-derived rotavirus isolates in
Caco2 cells but also in human intestinal organoids (Table S3). Treat-
ment with 100 ng/mL 6-TG inhibited patient-derived isolates in both
Caco2 cells (Fig. 1H) and human intestinal organoids (Fig. 1I). Hence,
6-TG signiﬁcantly counteracts rotavirus replication at clinically re-
levant concentrations.
3.2. Development of resistance to 6-TG is uncommon for rotavirus
Rotavirus was serially passaged in the presence of escalating con-
centrations of 6-TG to assess the potential of drug resistance develop-
ment. As a control, wild-type SA11 rotavirus was passaged in the ab-
sence of the drug. During the initial ten passages, infected cultures were
exposed to 1000 ng/mL of 6-TG; whereas the drug concentration was
increased to 2000 ng/mL at the subsequent later passages. After 20
passages, the eﬀects of 6-TG (100 ng/mL) on each representative pas-
sage (both drug treated and untreated) of rotavirus was quantiﬁed by
qRT-PCR. Our results indicate that rotavirus remains sensitive to 6-TG
treatment in MA104 cells (Fig. 2A) and Caco2 cells (Fig. 2B). Therefore,
rotavirus does not easily develop 6-TG resistance, suggesting that the
antiviral eﬀects of 6-TG likely depend on a cellular target but not a
direct interaction with the virus itself.
3.3. Rac1, the cellular target of 6-TG, sustains rotavirus replication
Although initially characterized as a nucleotide synthesis inhibitor,
in the last decade it has become clear that many of the eﬀects of 6-TG,
at least in gastrointestinal pathophysiology, depend on its potency to
inhibit Rac1 (Shin et al., 2016). Thus, we investigated the potential role
of Rac1 on rotavirus replication. To this end, we performed a lentiviral
RNAi-mediated loss-of-function assay to silence the Rac1 gene. Two
(no. 9689 and 9691) out of ﬁve RNAi vectors showed potent knock-
down of the target gene (Fig. 3A). Importantly, these two RNAi vectors
resulted in 65.0 ± 0.1% (n=10, P < 0.001) and 61.8 ± 0.2%
(n= 6, P < 0.05) reduction of SA11 rotavirus viral RNA, respectively
(Fig. 3B). In apparent agreement, we obtained Rac1 knockout mouse
embryonic ﬁbroblasts cells (MEFs), and their status as a bona ﬁde
knockout was conﬁrmed by western blot assay (Fig. 3C). Rotavirus
replication in Rac1 knockout MEFs (−/−) was signiﬁcantly less eﬃ-
cient (62.4 ± 0.2%; n=4; P < 0.05), compared with the replication
in wild type MEF (lf/lf) (Fig. 3D). Thus, decreased Rac1 levels correlate
with increased resistance towards rotavirus replication.
3.4. Eﬃcient rotavirus replication requires Rac1 activation
Rac1 acts as binary switch in cellular biochemistry, and it is only
capable of provoking signaling in the active GTP-bound form (Shin
et al., 2016). NSC23766, a speciﬁc GTP-Rac1 inhibitor was able to ef-
fectively inhibit GTP-Rac1 accumulation in Caco2 cells, as evident
when tested in GTP-Rac1 speciﬁc pull-down assay (Fig. 4A and B).
Importantly, treatment with either 5 or 25 μM NSC23766 for 48 h re-
sulted in 58.8 ± 0.1% (n=8; P < 0.05) and 77.48 ± 0.1% (n= 10;
P < 0.001) reduction on viral RNA levels, respectively (Fig. 4C). The
IC50 value of NSC23766 against SA11 rotavirus was 1.1× 10−8 M, the
CC50 of NSC23766 to Caco2 cells was 3.1× 10−4 M, and the SI was
2.8×104 (Table S2). The inhibitory eﬀect of NSC23766 on the rota-
virus infectious was further veriﬁed by a western blot assay, revealing
that treatment with either 1, 5 or 25 μM NSC23766 signiﬁcantly in-
hibits rotavirus VP4 protein synthesis in Caco2 cells (Fig. 4D). The ef-
fect of this drug was further conﬁrmed by experiments in human pri-
mary intestinal organoids, which indicated 91.1 ± 0.1% (n=6;
P < 0.05) reduction of viral RNA in the organoids (Fig. 4E) following
treatment with NSC23766.
Next, we tested the eﬀects of constitutively active and dominant
negative forms of Rac1 on rotavirus replication. This was done by
transfection of the active Rac1V12 plasmid or the dominant negative
Rac1N17 plasmid. Expression of both plasmids was successful when
tested by ﬂow cytometry (Fig. 4F). Accordingly, Rac1V12-transfected
cells displayed abundant GTP-Rac1, which in contrast is low in
Rac1N17-transfected cells, as determined in a Rac pull-down assay
(Fig. 4G). These results were conﬁrmed by analyzing abundance of
phospho-PAK2 status (Fig. 4H). Importantly, Rac1V12 promoted, but
Rac1N17 inhibited rotavirus replication (Fig. 4I). Taken together, ac-
tivation of Rac1 supports rotavirus replication.
Fig. 6. The eﬀects of the combination of 6-TG with IFNα, or ribavirin on rotavirus replication. (A) Treatment with IFNα (48 h) signiﬁcantly inhibited viral genomic
RNA in SA11 rotavirus infected Caco2 cells in a dose-dependent manner (n = 4, means ± SEM, **P < 0.01, Mann-Whitney test). (B) Treatment with IFNα (48 h)
remarkably inhibited viral VP4 protein in SA11 rotavirus infected Caco2 cells in a dose-dependent manner (The ratio of VP4/β-actin was expressed in arbitrary
units). (C) Eﬀect of the combination of various concentrations of 6-TG and IFNα on rotavirus replication in Caco2 cells. (D) Synergy plot representing the percentage
of antiviral activity above/below the expected activity for the 6-TG-IFNα combination based on the data shown in C. (E) Treatment with ribavirin (48 h) signiﬁcantly
inhibited viral genomic RNA in SA11 rotavirus infected Caco2 cells in a dose-dependent manner (n = 4–7, means ± SEM, *P < 0.05, **P < 0.01, Mann-Whitney
test). (F) Treatment with ribavirin (48 h) remarkably inhibited viral VP4 protein in SA11 rotavirus infected Caco2 cells in a dose-dependent manner (The ratio of
VP4/β-actin was expressed in arbitrary units). (G) Eﬀect of the combination of various concentrations of 6-TG and ribavirin on rotavirus replication in Caco2 cells.
(H) Synergy plot representing the percentage of antiviral activity above/below the expected activity for the 6-TG-ribavirin combination based on the data shown in G.
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3.5. 6-TG inhibits rotavirus via suppression of Rac1 GDP/GTP cycling
The inhibition of the activation of Rac1 by 6-TG was reported in
many cell types (Fuhler et al., 2008; Shin et al., 2016; Tiede et al.,
2003). Employing the Rac1 pull-down assay (Fig. 4A), we observed that
6-TG potently inhibited GTP-Rac1 accumulation; whereas corre-
sponding western blots did not show reduced overall Rac1 levels in
Caco2 cells following 6-TG treatment (Fig. 5A). Functional studies using
Rac1 knockdown Caco2 cells (Fig. 5B and C) were performed to de-
monstrate that both 6-TG and NSC23766 require Rac1 to combat ro-
tavirus replication. In agreement, pharmacological Rac1 inhibitors did
not inhibit rotavirus replication in Rac1 knockout MEF cells (Fig. 5D).
Thus 6-TG inhibits rotavirus via suppression of Rac1 activation.
3.6. 6-TG has no combination eﬀect with IFNα, but moderately antagonistic
eﬀect with ribavirin on rotavirus replication
Interferon-alpha (IFNα) and ribavirin are widely used as general
antivirals, being conﬁrmed to signiﬁcantly inhibit rotavirus replication
in vitro (Yin et al., 2015a). Consistently, we again demonstrated the
inhibitory eﬀects of IFNα and ribavirin on rotavirus RNA (Fig. 6A and
6E) and viral protein (Fig. 6B and F) in a dose-dependent manner. The
IC50 value of IFNα against SA11 rotavirus was 3.1× 10−5 IU, CC50 of
IFNα to Caco2 cells was 18706 IU, and SI was 6.0× 108 (Table S2). The
IC50 value of ribavirin against SA11 rotavirus was 1.6×10−7 M, CC50
of ribavirin to Caco2 cells was 3.02× 10−2 M and SI was 1.9×105
(Table S2). Next, we assessed the combinatory antiviral eﬀects of 6-TG
with IFNα or ribavirin. The combination of 6-TG and IFNα resulted in
no combination (no synergy or antagonism) antiviral eﬀect, with a
synergy volume of −2.8 μM2% (Fig. 6C and D). However, the combi-
nation of 6-TG and ribavirin resulted in moderately antagonistic anti-
viral eﬀect, with a synergy volume of −26.02 μM2% (Fig. 6G and H).
4. Discussion
In this study, we have demonstrated that 6-TG eﬀectively inhibits
rotavirus replication via inhibition of the Rac1 activity. This is parti-
cularly interesting in view that rotavirus replication is especially an
issue in organ transplantation recipients and in patients with IBD. 6-TG
is a therapeutic option for both groups of patients. Based on the ﬁndings
presented in the current study, the choice of 6-TG for these patients
appears rational, in particular when they are at risk of rotavirus in-
fection (Yin et al., 2015b).
Our results ﬁt well with the momentum of studies that document
antiviral activity of 6-TG. For instance, it has been reported that 6-TG
can combat Middle East respiratory syndrome coronavirus infection by
augmenting interferon responses (Cheng et al., 2015) and it has also
reported that Simian virus 40 DNA replication is antagonized by 6-TG
(Maybaum et al., 1987). Interestingly, it was reported that vaccinated
IBD patients had lower titers of hepatitis B surface antibody (HBsAb),
which might be inﬂuenced by the use of immunosuppressants including
6-TG (Watts et al., 2017).
As a 6-thiopurine (6-TP) prodrug, 6-TG is converted into pharma-
cologically active deoxy-6-thioguanosine phosphate (also called 6-
thioguanine nucleotide) and 6-thioguanosine phosphate (6-TGNP). 6-
TGNP can bind to Rac1 to form the 6-TGNP•Rac1 complex inactivating
Rac1 (Shin et al., 2016). As a major player of the Rho family of small
GTPases, Rac1 plays a vital role in various cellular signaling pathways
to regulate a wide variety of cell functions including gene transcription,
cell proliferation, apoptosis, motility, and redox signaling (D'Ambrosi
et al., 2014). The expression of Rac1 is ubiquitous, but it has two
conformational states including an inactive GDP-bound form and an
active GTP-bound form (Bosco et al., 2009). It exerts biological func-
tions mainly through activation of Rac1 (i.e. GTP-bound form) (Bosco
et al., 2009). Many viruses interfere with or employ the conformational
states of Rac1 to regulate their infection. At early stages of African
swine fever virus (ASFV) infection, Rac1 is activated, and inhibition of
Rac1 is able to suppress production of this virus (Quetglas et al., 2012).
Rac1 is found to be activated during intracellular mature virus (MV) of
Vaccinia virus entry (Mercer and Helenius, 2008).
Although rotavirus replication per se does not aﬀect the activation of
Rac1 (Fig. S4), we have demonstrated that the loss-of-function of Rac1
by gene knockdown or knockout signiﬁcantly impairs rotavirus re-
plication, which is in line with the previous ﬁnding that knockdown
Rac1 could signiﬁcantly inhibit Enterovirus 1 (EV1) infection
(Karjalainen et al., 2008). More speciﬁcally, the activation of Rac1 is
required as shown by the opposing eﬀects of ectopic over-expression of
the active or inactive forms of Rac1 on rotavirus replication. This me-
chanistically explains the potent anti-rotavirus eﬀects of the GTP-Rac1
inhibitors, 6-TG and NSC23766. Of note, NSC23766 has been shown to
inhibit the replication of several inﬂuenza viruses including a human
virus strain from the 2009 pandemic and highly pathogenic avian virus
strains (Dierkes et al., 2014).
Despite the absence of approved medications for treating rotavirus,
the widely used general antivirals including ribavirin and IFNα have
been studied on rotavirus in experimental models (Yin et al., 2015a).
Here, we have evaluated the combinatory eﬀects of 6-TG with IFNα or
ribavirin. Consistently, we conﬁrmed that ribavirin and IFNα inhibit
rotavirus replication at both RNA and protein levels (Fig. 6A and B). We
found increased potency of IFNα in the presence of 6-TG. However,
whether the combination of IFNα and 6-TG could be used to treat ro-
tavirus infected patients remains to be further investigated.
In conclusion, this study has demonstrated that 6-TG eﬀectively
inhibits rotavirus replication with a high barrier to drug resistance
development. We further identiﬁed the active form of Rac1 as an im-
portant host factor supporting rotavirus replication. 6-TG exerts its anti-
rotavirus eﬀects via the speciﬁc inhibition of Rac1 activation. Herein,
this study provided important references for clinicians to optimize
medications for organ recipients or IBD patients who are infected with
rotavirus or at risk of rotavirus replication. These results may also help
the development of new anti-rotavirus therapies.
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